Transvaginal progesterone: evidence for a new functional 'portal system' flowing from the vagina to the uterus
- PMID: 10465526
- DOI: 10.1093/humupd/5.4.365
Transvaginal progesterone: evidence for a new functional 'portal system' flowing from the vagina to the uterus
Abstract
The results of many recent experimental and clinical studies support the hypothesis that progesterone administered vaginally is distributed selectively to the uterus where tissue concentrations and effects exceed expectations. This phenomenon has multiple clinical implications in several fields of gynaecological endocrinology, notably in assisted reproductive treatments and new forms of hormone replacement therapy. Yet, the actual mechanisms by which vaginal administration of progesterone can induce higher concentrations in the uterus, despite low concentrations in the systemic circulation, remain obscure and most puzzling to many gynaecologists. This review aims to muster ideas and propose different mechanisms to explain the observed phenomenon. In particular, we will summarize data that support the various putative modes of transport including, direct diffusion through tissue, intracervical aspiration, absorption into the venous or lymphatic circulatory systems and countercurrent vascular exchange with diffusion from utero-vaginal veins/lymph vessels to arteries. All these mechanisms may concur to various extents to the uterine specificity of vaginal progesterone.
Similar articles
-
Targeted drug delivery in gynaecology: the first uterine pass effect.Hum Reprod. 1997 May;12(5):1073-9. doi: 10.1093/humrep/12.5.1073. Hum Reprod. 1997. PMID: 9194669
-
Direct transport of progesterone from vagina to uterus.Obstet Gynecol. 2000 Mar;95(3):403-6. doi: 10.1016/s0029-7844(99)00542-6. Obstet Gynecol. 2000. PMID: 10711552 Clinical Trial.
-
The first uterine pass effect.Ann N Y Acad Sci. 1997 Sep 26;828:291-9. doi: 10.1111/j.1749-6632.1997.tb48550.x. Ann N Y Acad Sci. 1997. PMID: 9329850 Review.
-
Mechanisms of uterine specificity of vaginal progesterone.Hum Reprod. 2000 Jun;15 Suppl 1:159-65. doi: 10.1093/humrep/15.suppl_1.159. Hum Reprod. 2000. PMID: 10928427 Clinical Trial.
-
Uses of progesterone in clinical practice.Int J Fertil Womens Med. 1999 Mar-Apr;44(2):96-103. Int J Fertil Womens Med. 1999. PMID: 10338267 Review.
Cited by
-
Design and development of novel inhibitors of aldo-ketoreductase 1C1 as potential lead molecules in treatment of breast cancer.Mol Cell Biochem. 2021 Aug;476(8):2975-2987. doi: 10.1007/s11010-021-04134-0. Epub 2021 Mar 26. Mol Cell Biochem. 2021. PMID: 33770316
-
Seminal plasma insemination during ovum-pickup--a method to increase pregnancy rate in IVF/ICSI procedure. A pilot randomized trial.J Assist Reprod Genet. 2013 Apr;30(4):569-74. doi: 10.1007/s10815-013-9955-7. Epub 2013 Feb 12. J Assist Reprod Genet. 2013. PMID: 23400375 Free PMC article. Clinical Trial.
-
New hope for preventing preterm birth: The promise of vaginal nanoformulations.Placenta Reprod Med. 2022;1:107. Epub 2022 Jul 6. Placenta Reprod Med. 2022. PMID: 36425736 Free PMC article. No abstract available.
-
Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques.Antimicrob Agents Chemother. 2012 Jan;56(1):103-9. doi: 10.1128/AAC.00597-11. Epub 2011 Oct 10. Antimicrob Agents Chemother. 2012. PMID: 21986823 Free PMC article.
-
Clinical trial considerations on male contraception and collection of pregnancy information from female partner: update.Clin Transl Med. 2016 Dec;5(1):23. doi: 10.1186/s40169-016-0103-8. Epub 2016 Jul 25. Clin Transl Med. 2016. PMID: 27455840 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources